Gilead uses Priority Review voucher for HIV regimen

Gilead Sciences Inc. (NASDAQ:GILD) submitted a Priority Review voucher along with an NDA to FDA for a single-tablet regimen combining its Emtriva emtricitabine and tenofovir alafenamide plus Edurant rilpivirine from Johnson & Johnson (NYSE:JNJ) to treat HIV-1 infection in patients aged 12 and older.

In November 2014, Gilead paid Knight Therapeutics Inc. (TSX:GUD) $125 million for the voucher, which was issued under FDA's tropical disease program (see BioCentury Extra, Nov. 19, 2014). ...